1. (1) Clozapine monitoring protocol requires enhanced record keeping and reporting to the drug manufacturer’s registry in order to dispense the medication. Dispensing pharmacy must meet all drug manufacturers requirements including data reporting.
2. (2) Clozapine monitoring includes documentation of client’s diagnosis, dosage, dosage changes, appropriate laboratory reports (e.g. white blood cell counts), evaluation intervals, and submission of appropriate information to drug manufacturer to allow dispensing of medication;
3. (3) Clozapine monitoring is to be billed using appropriate Medication Therapy Management Services (MTMS) Current Procedural Terminology (CPT) code with the modifier TC appended. This is limited to no more than 5 units in 30 day time period per client, including the 30 day period from the date of discontinuation of clozapine therapy;
4. (4) Clozapine monitoring must be billed by a pharmacy;
5. (5) MTMS rendered outside of clozapine management must be performed by a licensed pharmacist and must be billed to appropriately reflect the performing provider. These encounters must be billed using the appropriate MTMS CPT code without the TC modifier.

Statutory/Other Authority

ORS 413.042 & 414.065

Statutes/Other Implemented

ORS 414.065

History

DMAP 26-2013, f. & cert. ef. 6-25-13
DMAP 59-2012(Temp), f. 12-27-12, cert. ef. 12-28-12 thru 6-25-13
DMAP 44-2011, f. 12-21-11, cert. ef. 1-1-12
OMAP 61-2005, f. 11-29-05, cert. ef. 12-1-05
OMAP 9-2005, f. 3-9-05, cert. ef. 4-1-05
OMAP 18-2004, f. 3-15-04 cert. ef. 4-1-04
OMAP 57-2003, f. 9-5-03, cert. ef. 10-1-03
OMAP 40-2003, f. 5-27-03, cert. ef. 6-1-03
OMAP 20-2003, f. 3-26-03, cert. ef. 4-1-03
OMAP 45-2002, f. & cert. ef. 10-1-02
OMAP 31-2001, f. 9-24-01, cert. ef. 10-1-01
OMAP 17-2001, f. 3-30-01, cert. ef. 4-1-01
OMAP 1-1999, f. & cert. ef. 2-1-99
HR 6-1995, f. 3-31-95, cert. ef. 4-1-95
HR 20-1994, f. 4-29-94, cert. ef. 5-1-94